ライブ
FierceBiotechFDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient deathEndpoints NewsAbbVie faces questions about Skyrizi competition from J&JEndpoints NewsFDA, AstraZeneca prep for oncology adcommAgilentPCR Plate Sealer Market Leading Players Analysis - Agilent - openPR.comThermo FisherLeading biotech company launches its first US drug processing hub in Mass. - MassLive10x Genomics NewsWhy 10x Genomics Stock Is Sinking Today - TipRanksLonza NewsLonza Capsugel donates $50,000 to Project Hope Foundation - Index-JournalFierceBiotechAstraZeneca scraps FLAP inhibitor after flunking phase 2 asthma trialFierceBiotechRising costs push GE HealthCare to cut outlook as it restructures units and leadershipFierceBiotechTeva inks $700M Emalex buyout to bag near-approval Tourette drugFierceBiotechAstraZeneca restarts £300M investment in UK, but Merck not budgingCellSpatial organization and detection of social odors in mouse primary olfactory system
BioPharma Dive 2026年4月29日

Teva nabs experimental Tourette drug in $700M Emalex buyout

Teva nabs experimental Tourette drug in $700M Emalex buyout

原文
本文は利用できません。元の情報源をご確認ください。